Search Our Site

News tagged with:

"drug"

Opposite Day: Drug May Save Lives, So Drugmakers Offer To Cut Price

Praluent, a would-be breakthrough that targeted a heart attack gene, seemed doomed to go down in history as a pharmaceutical flop. But a new study — and an offer of discounts by its makers — may give it a second chance. In a study being presented at the annual meeting of the American College of... Read More »

Read More →

Praluent, a would-be breakthrough that targeted a heart attack gene, seemed doomed to go down in history as a pharmaceutical flop. But a new study — and an offer of discounts by its makers — may give it a second chance. In a study being presented at the annual meeting of the American College of… Read More »

[...]

Read More

HHS Secretary Alex Azar backs point-of-sale drug rebates by UnitedHealthcare, CVS Health

Director of Pharmacy Plan Services says Azar is out-of-touch as the discounts are unfair to healthier members of the plan who are footing the bill Cigna’s announcement that it is buying Express Scripts is the tip of the iceberg for what’s happening with insurers’ push to control the cost of prescription drugs. CVS Health’s proposed... Read More »

Read More →

Director of Pharmacy Plan Services says Azar is out-of-touch as the discounts are unfair to healthier members of the plan who are footing the bill Cigna’s announcement that it is buying Express Scripts is the tip of the iceberg for what’s happening with insurers’ push to control the cost of prescription drugs. CVS Health’s proposed… Read More »

[...]

Read More

Express Scripts plans see lower gains in prescription drug spending

Prescription drug prices may still be high, but Express Scripts says the commercial insurance plans it works with saw the lowest increase in drug spending last year in nearly a quarter of a century. For private employer and individual health plans, total drug spending rose 1.5 percent last year, according to the latest Express Scripts... Read More »

Read More →

Prescription drug prices may still be high, but Express Scripts says the commercial insurance plans it works with saw the lowest increase in drug spending last year in nearly a quarter of a century. For private employer and individual health plans, total drug spending rose 1.5 percent last year, according to the latest Express Scripts… Read More »

[...]

Read More

2017 drug approvals: Records, milestones, and controversies

In his first year as FDA Commissioner, Scott Gottlieb has chaperoned the agency through a blockbuster 2017 with 46 novel drug approvals to date. The final tally is the highest seen this century, surpassing the previous record holder 2015, which clocked in at 45. Both were more than double 2016’s sad tally of 22 new molecular... Read More »

Read More →

In his first year as FDA Commissioner, Scott Gottlieb has chaperoned the agency through a blockbuster 2017 with 46 novel drug approvals to date. The final tally is the highest seen this century, surpassing the previous record holder 2015, which clocked in at 45. Both were more than double 2016’s sad tally of 22 new molecular… Read More »

[...]

Read More

Experts Tell Congress How To Cut Drug Prices

The nation’s most influential science advisory group will tell Congress today that the U.S. pharmaceutical market is not sustainable and needs to change. “Drugs that are not affordable are of little value and drugs that do not exist are of no value,” said Norman Augustine, chair of the National Academies of Sciences, Engineering and Medicine’s... Read More »

Read More →

The nation’s most influential science advisory group will tell Congress today that the U.S. pharmaceutical market is not sustainable and needs to change. “Drugs that are not affordable are of little value and drugs that do not exist are of no value,” said Norman Augustine, chair of the National Academies of Sciences, Engineering and Medicine’s… Read More »

[...]

Read More

Pfizer Breast Cancer Drug Superior to Chemotherapy in Late Stage Study

(Reuters) – Patients with advanced breast cancer tied to an inherited gene mutation who were treated with an experimental Pfizer Inc drug went about three months longer before their disease worsened than those who received chemotherapy in a late stage study, according to data released on Friday. The drug, talazoparib, a once daily pill that... Read More »

Read More →

(Reuters) – Patients with advanced breast cancer tied to an inherited gene mutation who were treated with an experimental Pfizer Inc drug went about three months longer before their disease worsened than those who received chemotherapy in a late stage study, according to data released on Friday. The drug, talazoparib, a once daily pill that… Read More »

[...]

Read More

California Governor Signs Law To Make Drug Pricing More Transparent

California Gov. Jerry Brown defied the drug industry Monday, signing the most comprehensive drug price transparency bill in the nation that will force drug makers to publicly justify big price hikes. “Californians have a right to know why their medical costs are out of control, especially when pharmaceutical profits are soaring,” Brown says. “This measure... Read More »

Read More →

California Gov. Jerry Brown defied the drug industry Monday, signing the most comprehensive drug price transparency bill in the nation that will force drug makers to publicly justify big price hikes. “Californians have a right to know why their medical costs are out of control, especially when pharmaceutical profits are soaring,” Brown says. “This measure… Read More »

[...]

Read More

How to cover Novartis’ $475K CAR-T drug Kymriah? A ‘new payment model’ is the only way, Express Scripts says

Steve Miller, the chief medical officer of Express Scripts, is one of the loudest voices in the ongoing debate over high drug prices, so it was only a matter of time before he weighed in on Kymriah, Novartis’ $475,000 CAR-T treatment for some patients with leukemia. That time came yesterday, and Miller didn’t mince words... Read More »

Read More →

Steve Miller, the chief medical officer of Express Scripts, is one of the loudest voices in the ongoing debate over high drug prices, so it was only a matter of time before he weighed in on Kymriah, Novartis’ $475,000 CAR-T treatment for some patients with leukemia. That time came yesterday, and Miller didn’t mince words… Read More »

[...]

Read More

Judge refuses to block Maryland price-gouging law

Opponents of a new law allowing Maryland to challenge generic drug price-gouging lost the first round of a legal battle Friday as a federal judge refused to block the measure. U.S. District Judge Marvin J. Garbis turned down a plea by a pharmaceutical industry group to issue an injunction against the law, which takes effect... Read More »

Read More →

Opponents of a new law allowing Maryland to challenge generic drug price-gouging lost the first round of a legal battle Friday as a federal judge refused to block the measure. U.S. District Judge Marvin J. Garbis turned down a plea by a pharmaceutical industry group to issue an injunction against the law, which takes effect… Read More »

[...]

Read More

When a Drug Coupon Helps You but Hurts Fellow Citizens

It’s completely rational for you to use coupons to lower the cost of your brand-name drug purchase. But if the coupon is causing you to switch away from a generic drug with an overall lower cost, you may be playing a role in pushing up drug spending and premiums for others. Let’s say that I... Read More »

Read More →

It’s completely rational for you to use coupons to lower the cost of your brand-name drug purchase. But if the coupon is causing you to switch away from a generic drug with an overall lower cost, you may be playing a role in pushing up drug spending and premiums for others. Let’s say that I… Read More »

[...]

Read More

Page 1 of 2

Categories
Archives